EDITORIAL SECTIONS
RESEARCH & DEVELOPMENT
Adopting the Power of AI to Drug Development Projects
A tremendous amount of documentation is created throughout the clinical trial lifecycle
CLINICAL TRIALS
Real-world Evidence
Hearing the diagnosis from the doctor that your child has spinal muscular atrophy SMA
MANUFACTURING
Just in Time Manufacturing Creating more sustainable supply chains
Drug development has transformed immeasurably over the past decade Even before the Covid pandemic and the conflict in Ukraine
Information Technology
Challenges and Advantages of Using Artificial Intelligence in Pharma
Many advanced largescale AI initiatives still need to be proved successful in Pharma
KNOWLEDGE BANK
Interviews
From Single-Cell to Spatial Intelligence: The Next Era of Precision Medicine
Founder & Strategic Advisor, Genomics Consult
Dr Elsa Molina is a PhDtrained biologist and strategic scientific leader specializing in singlecell genomics spatial omics and nextgeneration sequencing technologies With over eight years of experience at the Salk Institute and University of California San Diego her background spans Europe Australia and North America Dr Molina is Founder Strategic Advisor at Genomics Consult advising on translati...
Articles
Multi-Target Directed Ligands and Lipidomics Approach for Glioblastoma Drug Discovery
The traditional pharmaceutical approach of designing a diseasesymptomspecific drug has historically proven effective However this methodology often falls short due to the complex and often multifactorial etiology of diseases
Research Insights
Feasibility and Cost-Effectiveness of Treating Multidrug-Resistant Tuberculosis: A Cohort Study in the Philippines
Thelma E Tupasi Rajesh Gupta Ma Imelda D Quelapio Ruth B Orillaza Nona Rachel Mira Nellie V Mangubat Virgil Belen Nida Arnisto Lualhati Macalintal Michael Arabit Jaime Y Lagahid Marcos Espinal Katherine Floyd
Case Studies
Effect Of Process And Formulation Variables On The Preparation Of Parenteral Paclitaxel-loaded Biodegradable Polymeric Nanoparticles: A Co-surfactant Study
Abstract Recent years have seen significant effort devoted to formulate therapeutic agents in biocompatible nanocomposites such as nanoparticles nanocapsules micellar systems and conjugates as drug delivery systems Application of nanotechnology for diagnosis monitoring disease therapy and control of biological systems was referred to as nanomedicin
Techno Trends
China's New Drug Approval Process Streamlined to Boost Biopharma Innovation
China has revised its drug approval process aiming to expedite the launch of innovative biopharmaceuticals
White Papers
Cloud Computing in the Laboratory Informatics Solutions and Validation Approaches
In the modern business environment, a significant portion of work is conducted using computerized systems. Many solutions are used to complete tasks, including simple desktop programs like email and Microsoft Office to enterprise-wide, global systems like ERP (Enterprise Resource Planning), MES (Manufacturing Execution System), and LIMS
TOP ARTICLES
The Rapidly Evolving Landscape of Cancer Therapeutics
Rajesh Kumar is an Assistant Professor of Pharmaceutical Sciences at Kerala University of Health Sciences, India. He has been teaching Diploma, Bachelor, and Doctor of Pharmacy students for several years and is actively involved in research. He has authored more than 19 papers and is a reviewer for Bentham Science Publishers. His research includes applying the principles of pharmaceutical sciences, omics technologies, computational biology, and bioinformatics in the broad areas of cancer research, ethnopharmacology, drug delivery, targeting, and formulations.
Seetha Harilal is an Assistant Professor of Pharmacology at Kerala University of Health Sciences, India. She has several years of experience in teaching Diploma, Bachelor, and Doctor of Pharmacy students and is actively pursuing research. She has authored more than 22 papers and is a manuscript reviewer for Bentham Science Publishers, Frontiers in Public Health, Frontiers in Medicine, and Archives of Medical Research (Elsevier). Her research includes the diverse areas of pharmacology and therapeutics, phytopharmaceuticals, cancer research, neurological disorders, and the application of omics technologies, computational pharmacology, and bioinformatics.
Repurposed Drugs against the Latest Variants of Concerns of SARS-CoV-2
Sinosh Skariyachan Ph.D. is presently working as Assistant Professor in Microbiology at St. Pius X College, Rajapuram (Aided by Govt. of Kerala, India), Kasaragod, Kerala, India with more than 17 years of experience in teaching and research. One of his key areas of research is computational drug discovery and medicinal chemistry. He has published more than 75 international papers, book chapters, and text books. He is the editor of prestigious journals such as Computers in Biology and Medicine (Elsevier), Frontiers in Microbiology and a referee for more than 125 international journals. He received several awards and grants.
Envisioning the Biomanufacturing Facility of the Future
Merrilee is the Head of the BioContinuum™ Platform, driving the strategy and execution of Process Intensification Technologies, Software & Automation, and Analytics to meet the needs of biologics manufacturers. Throughout her 15 years at MilliporeSigma, she managed multiple product lines including clarification, aseptic, virus filtration, and Single Use & Systems.
Current Research on Plant miRNA and Its Application in Disease Prevention
Atiya Saiyed is a Ph D student at Iladevi Cataract and IOL Research Centre and registered at Manipal Academy of Higher Education, Manipal. She is Senior Research Fellow from Indian Council of Medical Research, New Delhi. Atiya does research in the fields of molecular biology, cell biology, and cancer biology.
Abhay R. Vasavada is a well-known ophthalmologist who founded Raghudeep Eye Clinic (REH) and Iladevi Cataract and IOL Research Centre (ICIRC) in Ahmedabad, India. In 2011, the American Society of Cataract and Refractive Surgeons (ASCRS) gave him the Binkhorst Medal Lecture, making him the first Indian and just the second Asian to get the honour. He has almost 140 publications to his credit.
Kaid Johar SR is an Associate Professor in Department of Zoology and Biomedical TechnologyGujarat University, who specialized in cell and molecular biology, ophthalmology, cancer, and toxicology. He has almost 50 publications in prestigious journals.
Natural Polymers and Fibers in Drug Delivery
Dr. Meghraj V. Suryawanshi is an Associate Professor and Co-Founder of Sandip Institute of Pharmaceutical Sciences. He holds M.Pharm, MBA, PDCR, and Ph.D. degrees. With over 7 years of research experience and 4 years in teaching, his expertise lies in polymer science, novel drug delivery systems (NDDS), and intellectual property rights (IPR). Dr. Suryawanshi has authored more than 55 publications, 8 books, and holds several patents. He actively leads innovative pharmaceutical research with a strong focus on translational impact.
Akshata Yashwant Patne is a pharmaceutical nanotechnology expert with over 3 years of experience in clinical research, drug delivery, and AI-driven therapeutics. She has led nanoparticle-based studies, published peer-reviewed articles, and actively mentors students, combining science, innovation, and leadership across academia, research, and global scientific communities.
press releasesRead more...
Merck Opens €300 Million Asia-Pacific Bioprocessing Center in Daejeon, South Korea
Merck a leading science and technology company today opened its new AsiaPacific Bioprocessing Production Center in Daejeon South Korea The center represents an investment of more than million the companys largest Life Science investment in AsiaPacific to date
Flagship Pioneering Forms Etcelera to Move Drug Discovery from Probability to Prediction
Flagship Pioneering a scientific innovation engine for transformative platforms and products today announced the formation of Etcelera a company created by the merger of the platforms of Cellarity Cellarity Platform Inc Etiome and Empress Therapeutics to pioneer causal intelligence in human biology...
Junshi Biosciences Announces Acceptance of the Supplemental New Drug Application of Toripalimab (Subsutaneous Injection) for the 1st-Line Treatment of HER2-Expressing Urothelial Carcinoma
Shanghai Junshi Biosciences Co Ltd a leading innovationdriven biopharmaceutical company dedicated to the discovery development and commercialization of novel therapies announced that the supplemental new drug application for the companys product toripalimab injection subcutaneous injection
HUTCHMED Announces Sovleplenib Granted US FDA Orphan Drug Designation for Primary Immune Thrombocytopenia
HUTCHMED China Limited today announces that the US Food and Drug Administration FDA has granted Orphan Drug Designation to sovleplenib for the treatment of primary immune thrombocytopenia ITP an autoimmune disorder that can lead to increased
Transpharmation Ltd. Announces Strategic Acquisition of OrganoTherapeutics SARL
Were delighted to announce the strategic acquisition of OrganoTherapeutics SARL a leader in patientderived organoid technologies that advance the discovery and development of novel therapies for neurodegenerativeCNS disorders
EVERSANA Expands Global Commercialization and AI-Powered HEOR Capabilities with Acquisition of U.K.-based Estima Scientific
EVERSANA a global provider of modern AIpowered commercial services for the biopharmaceutical industry today announced the acquisition of Estima Scientific an innovative Londonbased health economics and outcomes research HEOR technology and services company
EventsRead more...
02 - 04
Nov 2026Pharma Forum EMEA 2026
Dom Pedro Lisboa Hotel, Lisbon...
02 - 04
Nov 2026Cancer R&D 2026
Houston, TX, USA
03 - 05
Nov 202610th Dermatology Drug Development
Boston, Massachusetts at The C...
03 - 04
Nov 2026PDA Aseptic Processing of Biopharma Conference
Sheraton Grand Incheon Hotel,...
04 - 05
Nov 2026Advanced Therapies USA
Hynes Convention Center, Bosto...
05 - 05
Nov 2026PDA Contamination Control Strategy Workshop
Sheraton Grand Incheon Hotel,...
09 - 11
Nov 202611th Microbiome Movement USA Summit
The Colonnade Hotel, Boston, M...
10 - 11
Nov 2026Extractables & Leachables Europe
Parkhotel Schӧnbrunn, Vienna,...
LATEST NEWSRead more...
Edison Scientific Enters into Agreement with Pfizer to Advance Drug Research and Development
Edison Scientific has entered into an agreement with Pfizer to introduce its Edison AI Platform and AI scientist Kosmos across Pfizers biopharmaceutical research and development activities The collaboration will combine Edison Scientifics artificial intelligence AI technology with Pfizers scientific...
Appian and PSI CRO Partner to Advance AI-driven Clinical Trial Operations
Appian and PSI CRO have entered into a strategic partnership to introduce an artificial intelligence AIpowered solution for clinical trial site identification and selection The solution is now live and is designed to automate site selection across different therapeutic areas medical conditions and...
Adalvo Acquires Romiplostim Biosimilar from Enzene
Adalvo has acquired a romiplostim biosimilar programme from Enzene expanding its portfolio of biosimilars and strengthening its presence in complex biological medicines The programme references Nplate romiplostim a medicine used to treat immune thrombocytopenia ITP in adults and children with chroni...
Twist Bioscience Launches Express Screening Antibodies for Faster Characterisation
Twist Bioscience has expanded its antibody production and characterisation portfolio with the launch of Twist Express Screening Antibodies a service designed to help researchers evaluate large numbers of antibody candidates more quickly The service uses a highthroughput cellfree production process t...
Astellas Enters into Agreement with Audax for Immuno-Oncology Candidate DAX-044
Astellas Pharma and Audax Biosciences have entered into an exclusive option and licence agreement for DAX an investigational antibodycytokine fusion being developed for cancer immunotherapy DAX is designed to deliver interleukin IL an immuneactivating protein more selectively to the tumour microenvi...
Sumitomo Pharma’s Enzomenib Receives Breakthrough Therapy Designation for Relapsed or Refractory KMT2A-Rearranged Acute Leukaemia
Sumitomo Pharma America has announced that the US Food and Drug Administration FDA has granted Breakthrough Therapy designation to enzomenib DSP for treating patients with relapsed or refractory acute leukaemia carrying a KMTA gene rearrangement